← All causality assessments
Causality assessment · Coding artifact: the indication reported back as the "reaction"

Salmeterol Xinafoate and Asthma: is the FAERS signal real?

n=910 co-reports · PRR 20.0 · ROR 22.3
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Coding artifact: the indication reported back as the "reaction"

Salmeterol Xinafoate ↔ Asthma

n=910 co-reports · PRR 20.0 · ROR 22.3

Carbidopa, levodopa, entacapone (Stalevo) is a combination for Parkinson disease. The co-reporting of Parkinson as a reaction is a coding artifact: patients on Stalevo for Parkinson have the indication recorded as the AE. 2,169 co-reports (PRR 13.4) reflect the treated population.

Coding artifact: Parkinson is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Salmeterol captured asthma as a tracked adverse event in a usable structure. Parkinson is the indication; trials do not track it as an AE.